Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Aims To estimate the incidence of newly diagnosed idiopathic stroke among users of fenfluramine, dexfenfluramine and phentermine compared to obese nonusers. Methods We conducted a cohort study with nested case‐control analysis utilizing data from the General Practice Research Database in the UK. Eight thousand four hundred and twenty‐three subjects aged 69 years or less at the start of follow‐up were exposed to at least one of the three study drugs and 17 225 similarly obese subjects were not exposed to any of the study drugs. Results We identified 45 incident cases of idiopathic CVA in this cohort of subjects. The incidence of CVA among all current users of a diet drug was 1.3/1000 person‐years (95% CI 0.5, 3.5). The incidence for current fenfluramine users (n=2) was 2.6/1000 person‐years (95% CI 0.7, 9.6), for current dexfenfluramine users (n=1) 1.1/1000 person‐years (95% CI 0.3, 3.8), and for current phentermine users 0/1000 person‐years (95% CI 0.0, 12.9). The incidence in obese nonusers was 0.6/1000 person‐years (95% CI 0.4, 0.9). The adjusted matched odds ratio (OR) for thrombotic stroke from the case‐control analysis comparing current use of a diet drug to nonuse was 2.4 (95% CI 0.6, 9.1). There was only one exposed subject among seven who had haemorrhagic stroke. Conclusions The incidence of CVA in generally young obese subjects during use of fenfluramine, dexfenfluramine or phentermine is low. Although we found an OR of 2.4 comparing users of any of the anorexiants with nonusers, this is based on only three exposed cases and the confidence limits are wide. We conclude that our study does not support a substantial increased risk of stroke attributable to the use of fenfluramine, dexfenfluramine or phentermine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Jick, H., Jick, S. S., & Derby, L. E. (1991) · BMJ · doi:10.1136/bmj.302.6779.766 · Cited by 839
Self-citationA Prospective Study of Body Mass Index, Weight Change, and Risk of Stroke in Women
Rexrode, K. M. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540430051032 · Cited by 617
Cited by
The General Practice Research Database: Role in Pharmacovigilance
Wood, L., & Martinez, C. (2004) · Drug Safety · doi:10.2165/00002018-200427120-00004 · Cited by 331
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Schmid, C. H., & Lau, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004096.pub2 · Cited by 113
Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN)
Ruigómez, A., Martín‐Merino, E., & Rodríguez, L. A. G. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1919 · Cited by 89
Richardson, K., Loke, Y. K., Fox, C., Maidment, I., Howard, R., Steel, N., Arthur, A., Boyd, P. J., Aldus, C., Ballard, C., et al. (2020) · BMC Medicine · doi:10.1186/s12916-020-01821-5 · Cited by 73
Ahmad, N. N., Robinson, S., Kennedy‐Martin, T., Poon, J. L., & Kan, H. (2021) · Obesity Reviews · doi:10.1111/obr.13326 · Cited by 69
“In two nested case–control studies that used data from the UK CPRD, no increase in the incidence of stroke or cardiac-valve abnormalities was observed in patients treated with phentermine.(28,39) In a US retrospective cohort study that used data from electronic medical records, it was demonstrated that there was no in…”
Method
Metadata
- Authors
- Derby, L. E., Myers, M. W., & Jick, H.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1999-05
- Volume
- 47
- Issue
- 5
- Pages
- 565-569
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1643550007
- Cited by
- 34
- References
- 3
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke. https://app.cochat.ai/papers/10.1046/j.1365-2125.1999.00928.x
- The paper
- Derby, L. E., Myers, M. W., & Jick, H. (1999). Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.1999.00928.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.